Conductive Polymer Microneedle Arrays for Localized Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spinal cord and brain injuries, such as methylprednisolone, have systemic side effects and require invasive procedures like durotomy, which can lead to complications like CSF leaks and infections, highlighting the need for a therapeutic delivery system that can administer drugs locally without damaging the dura mater.
Innovation Solution
A microneedle array with a conductive coating containing a therapeutic agent and a conducting polymer is implanted in the dura mater, allowing for controlled release of the agent through electrical stimulation, thereby minimizing the need for surgical incisions and reducing systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional systemic drug delivery methods are used, then therapeutic agents can reach the central nervous system, but systemic side effects occur and invasive procedures like durotomy are required
Solution Approach 1:
The invention divides the drug delivery system into multiple microneedles that can be individually implanted through the dura mater, allowing localized drug release at specific sites without requiring extensive surgical opening. Each microneedle acts as an independent delivery unit with conductive coating for controlled release
Solution Approach 2:
The patent implements local drug delivery by placing microneedles directly at the injury site within the central nervous system. The conductive coating on each microneedle enables localized electrical stimulation-triggered drug release, concentrating therapeutic effect at the target site while avoiding systemic distribution and associated side effects
2Ease of operation
If durotomy is performed for drug delivery, then therapeutic agents can be administered to the central nervous system, but risks of CSF leak, meningitis, and spinal cord damage increase
Solution Approach 1:
Instead of performing a single large durotomy, the invention uses multiple small microneedles that can penetrate the dura mater with minimal damage. The segmented approach creates small puncture sites rather than a large opening, significantly reducing the risk of CSF leak and infection while maintaining effective drug delivery access
Solution Approach 2:
The patent replaces the mechanical surgical blade incision with a less invasive microneedle penetration system. The microneedles can be inserted with minimal mechanical force, and the conductive coating enables electrical control of drug release, substituting mechanical surgical intervention with a more precise and safer minimally invasive approach
3Adaptability or versatility
If large molecule and protein therapeutics are used, then treatment options are expanded, but the blood-brain barrier prevents their delivery
Solution Approach 1:
The invention extracts the drug delivery problem from the constraint of the blood-brain barrier by using direct microneedle implantation into the central nervous system. This bypasses the need for drugs to cross the blood-brain barrier, enabling delivery of large molecule and protein therapeutics that would otherwise be restricted to single bolus delivery through dural punctures
4Reliability
If controlled local delivery is implemented, then side effects are reduced and efficacy is improved, but the complexity of the delivery system increases
Solution Approach 1:
The microneedle array serves multiple functions: mechanical penetration of the dura mater, localized drug delivery, and electrical stimulation response. The conductive coating provides both structural integrity and electrical conductivity, enabling a single component to perform multiple roles and reducing overall system complexity despite the advanced functionality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables localized, controlled delivery of therapeutic agents directly to the central nervous system, reducing neuroinflammation and minimizing damage to the dura mater, while allowing higher doses of medication to be administered safely, thus improving treatment efficacy and reducing risks associated with traditional methods.
Implementation Method 1
applying an electrical stimulus to the microneedle array to provide a controlled release of the therapeutic agent from the conductive coating
Data Source
AI summary
The present disclosure describes a method of delivering a therapeutic agent providing a microneedle array including a plurality of microneedles, the plurality of microneedles including a conductive coating disposed thereon, wherein the conductive coating includes the therapeutic agent and a conducting polymer; implanting the microneedle array in a dura mater of a subject in need thereof, wherein the microneedle array pierces the dura mater; and applying an electrical stimulus to the microneedle array to provide a controlled release of the therapeutic agent from the conductive coating, across the dura mater, to the central nervous system of the subject.